# UNIVERSITY BIRMINGHAM University of Birmingham Research at Birmingham

# The epidemiology of UK autoimmune liver disease varies with geographic latitude

Webb, Gwilym; Ryan, Ronan; Marshall, Tom; Hirschfield, Gideon

DOI: 10.1016/j.cgh.2021.01.029

License: Creative Commons: Attribution (CC BY)

*Document Version* Version created as part of publication process; publisher's layout; not normally made publicly available

Citation for published version (Harvard):

Webb, G, Ryan, R, Marshall, T & Hirschfield, G 2021, 'The epidemiology of UK autoimmune liver disease varies with geographic latitude', *Clinical Gastroenterology and Hepatology*, vol. 2021, no. 00, pp. 1-55. https://doi.org/10.1016/j.cgh.2021.01.029

Link to publication on Research at Birmingham portal

#### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

#### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

#### RTICLE IN PR

# The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude

Gwilym J. Webb,\*,<sup>‡</sup> Ronan P. Ryan,<sup>§</sup> Tom P. Marshall,<sup>§</sup> and Q38 Gideon M. Hirschfield\*,

Q14

Q15 

> \*National Institute for Health Research, Birmingham Biomedical Research Centre, <sup>§</sup>Primary Care Clinical Sciences, Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom; <sup>‡</sup>Cambridge Liver Unit, Addenbrooke's Hospital, Cambridge, United Kingdom; Division of Gastroenterology and Hepatology, Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada

10			
16 17	Q11	BACKGROUND& AIMS:	The epidemiology of autoimmune liver disease (AILD) is challenging to study because of the diseases' rarity and because of cohort selection bias. Increased incidence farther from the
18			Equator has been reported for multiple sclerosis, another autoimmune disease. We assessed
19			the incidence of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and
20			autoimmune hepatitis (AIH) in relation to latitude.
21			
22		METHODS:	We performed a retrospective cohort study using anonymized UK primary care records from
23	Q12		January 1, 2002, to 2016-05-10. All adults without a baseline diagnosis of AILD were included
24			and followed up until the first occurrence of an AILD diagnosis, death, or they left the database.
25			Latitude was measured as registered general practice rounded down to whole degrees.
26			
27		RESULTS:	The cohort included 8,590,421 records with 53.3 $ imes$ 10 <sup>7</sup> years of follow-up evaluation from 694
28			practices. There were 1314 incident cases of PBC, 396 of PSC, and 1034 of AIH. Crude incidences
29			were as follows: PBC, 2.47 (95% CI, 2.34–2.60); PSC, 0.74 (95% CI, 0.67–0.82); and AIH, 1.94
30			(95% CI, 1.83-2.06) per 100,000 per year. PBC incidence correlated with female sex, smoking,
31			and deprivation; PSC incidence correlated with male sex and nonsmoking; AIH incidence
32			correlated with female sex and deprivation. A more northerly latitude was associated strongly
33			with incidence of PBC: 2.16 (95% CI, 1.79–2.60) to 4.86 (95% CI, 3.93–6.00) from $50^{\circ}$ N to $57^{\circ}$ N (B = 0.02) and incidence of AUL 2.00 (05% CI 4.65–2.42) to 2.29 (05% CI 2.52, 4.24) (B =
34			(P = .002) and incidence of AIH: 2.00 (95% CI, 1.65–2.43) to 3.28 (95% CI, 2.53–4.24) $(P = .003)$ , but not incidence of PSC: 0.82 (95% CI, 0.60–1.11) to 1.02 (95% CI, 0.64–1.61) $(P = .473)$ .
35			Incidence after adjustment for age, sex, smoking, and deprivation status showed similar posi-
36			tive correlations for PBC and AIH with latitude, but not PSC. Incident AIH cases were younger at
37			greater latitude.
38			
		CONCLUSIONS:	We describe an association in the United Kingdom between increased latitude and the inci-
39		0011010310113.	dence of PBC and AIH that requires both confirmation and explanation.
40			uchee of 1 be and Am that requires both commination and explanation.
41			

Keywords: Autoimmune Liver Disease; Latitude; Primary Biliary Cholangitis; Primary Sclerosing Cholangitis; Autoimmune Hepatitis.

The 3 major autoimmune liver diseases (AILDs), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH), represent significant causes of liver morbidity and mortality whose etiopathogenesis is incompletely understood.<sup>1–3</sup> Although individually uncommon, together they account for a significant proportion of elective liver transplantation,<sup>4</sup> and the incidence and prevalence appear to be increasing.<sup>5–8</sup>

To date, genetic association studies only have been able to explain a minority of the risk for the 3 AILDs, suggesting a significant role for environmental factors.<sup>9</sup> A number of environmental factors have been identified

as associated with risk of AILD including urinary tract infections, nail polish use, hair dye use, smoking, and deprivation in PBC<sup>10-14</sup>; smoking as a negative risk factor in PSC<sup>15,16</sup>; and various drug exposures in

Abbreviations used in this paper: AIH, autoimmune hepatitis; AILD, autoimmune liver disease; IQR, interquartile range; MS, multiple sclerosis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; THIN, The Health Improvement Network.

© 2021 by the AGA Institute. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/). 1542-3565

https://doi.org/10.1016/j.cgh.2021.01.029

#### 2 Webb et al

AIH.<sup>3,17,18</sup> However, even in aggregate, these factors 117 118 appear insufficient to explain variations in individual 119 disease risk.9

120 Latitude has been proposed as a risk factor for 121 AILDs because of its link to vitamin D status and in 122 turn the link between vitamin D status and risk of 123 Q16 autoimmunity.<sup>19-23</sup> T<sub>H</sub>1 T-cell activation and B-cell 124 activation are implicated in each of the AILDs, and 125 activation is regulated negatively by physiological concentrations of vitamin D.1-3,22 The association be-126 tween the neurologic autoimmune disease multiple 127 sclerosis (MS) and latitude is well established.<sup>24,25</sup> For 128 129 type 1 diabetes, childhood hypovitaminosis D has been 130 associated with increased disease risk.<sup>26</sup> By analogy, 131 similar associations with latitude exposure have been 132 shown in other autoimmune conditions and latitude 133 has been suggested as a target for investigation among 134 the AILDs, but to date such an assessment has not 135 been performed.<sup>21,27</sup>

136 In this study we investigated the relationship be-137 tween latitude and incidence of AILD in a large UK pri-138 mary care database with established generalizability to the national population.<sup>28</sup> We also describe disease 139 140 prevalence and assess disease associations with age, sex, 141 deprivation, smoking, and ethnicity. 142

#### Methods

143

144

145

146

147

163

164

165

166

167

168

169

170

171

#### Study Design and Population

A retrospective cohort study was performed using the 148 pseudonymized primary care health records contained in 149 The Health Improvement Network (THIN) database be-150 tween January 1, 2002, and 2016-05-10.29 THIN is a UK-151 based primary care database containing routinely 152 collected electronic patient records. At each consultation, 153 general practitioners record details of the medical 154 encounter, including diagnosis. Demographic details such 155 as age, sex, and linked deprivation scores also form part 156 of the electronic record. Deprivation is based on a com-157 bination of scores for home ownership, car ownership, 158 unemployment, and household overcrowding, and is 159 adjusted so that the country is represented as 5 equally 160 sized quintiles as originally described by Townsend<sup>30</sup> 161 in 1987. 162

#### Inclusion Criteria

Patients of all ages registered with a practice contributing to THIN during the study period.

#### Exclusion Criteria

Patients with a previous diagnosis of AILD at baseline 172 were excluded. Patients with potential overlap of auto-173 immune liver diseases were excluded (see later). 174

## What You Need to Know

#### Background

Disease risk in primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis are insufficiently explained by genetic factors. In other autoimmune diseases such as multiple sclerosis, geographic latitude correlates with disease risk.

#### **Findings**

We show a novel association between increased geographic latitude and disease incidence of primary biliary cholangitis and autoimmune hepatitis, but not primary sclerosing cholangitis, in a large UK primary care population.

#### Implications for patient care

Although these findings require confirmation in other populations, they inform further exploration of pathogenic mechanisms influencing disease risk such as vitamin D deficiency.

#### Follow-Up Evaluation

Patients were followed up until death, leaving a contributing practice, the date that a practice stopped contributing to THIN, or the end of the study period, whichever was latest.

#### Exposure

Latitude was measured by geocoding latitude from the postal code of the general practice concerned. This was performed by THIN to avoid identification of individual practices; the locations of individual practices were not available to the authors. Latitude was rounded down to the nearest integer. Because of the small population residing in the  $58^{\circ}$  latitude band, the residents at  $58^{\circ}$  were combined with the residents at 57° for analysis. Townsend<sup>30</sup> quintiles were calculated from the postcode of place of residence by THIN. Covariable data on age, sex, smoking status, and ethnicity were collected from general practice records. The most recently submitted data in each category at the end of the follow-up period were used in each case.

#### Outcomes

Diagnoses of AILDs were defined using diagnostic codes (Supplementary Table 1). For PBC and PSC, a single diagnostic code specific to the respective condition 226 was identified; for AIH, a combination of 3 potential 227 codes validated in a previous study was used.<sup>31</sup> Of note, 228 in contrast to the International Classification of Diseases Q17 229 system of diagnostic codes, the Read code system used in 230 UK general practice contains a specific term for PSC. For 231 use as positive and negative controls of conditions with 232

175

176

177

178

179

180

Q13

193 194

195

196

197

198

199

208

209

210

211

216

217

221 2.2.2




Figure 1. Incidence of autoimmune liver disease by latitude. Top row: Plots denote crude incidence of (A) primary biliary cholangitis (PBC), (B) primary sclerosing cholangitis (PSC), and (C) autoimmune hepatitis (AIH). (D-F) Bottom row: Plots denote adjusted incidence after adjustment for sex, age, smoking status, and Townsend<sup>30</sup> deprivation quintile. For PBC and AIH there was a significant increase in incidence at more northerly latitudes both before and after adjustment; for PSC a significant correlation was not present.

and without published associations with latitude, cases of MS and hypertension were examined using standard diagnostic codes (Supplementary Table 1).

Cases with 2 or more lifetime diagnoses of different AILDs (ie, cases of possible autoimmune overlap) were not considered to represent incident disease for any AILD diagnosis. Cases were considered incident if the date of their first recording was more than 1 year after the individual's registration at the practice concerned, and also 1 year after the practice had achieved acceptable mortality reporting.<sup>32</sup> This was to prevent preexisting diagnoses appearing incident in new registrations at a particular general practice.<sup>33</sup>

Data regarding the Townsend<sup>30</sup> deprivation quintile were provided by THIN and derived from the postal code of the patient's residence. Latitude bands were provided by THIN at special request and were derived from the practice postal code.

All data used were those most recent at the end of the follow-up period for a given individual.

#### Statistical Analyses

All data were analyzed using Stata v15.2 (StataCorp, 288 Q18 College Station, TX) using the Birmingham BlueBEAR high performance computer cluster. We present descriptive sta-tistics, univariable analysis of associations between risk factors and incidence, and multivariable analysis with adjustments for sex, age, smoking status, Townsend<sup>30</sup> deprivation quintile, and latitude. Where data were adjusted for covariables, direct standardization was used. Where direct standardization was used to adjust for multiple covariables, individuals with missing data in any category were excluded. For the examination of trends over time, latitude, or quintiles of deprivation, a least-squares linear regression was performed. For assessing for changes in sex ratios, the chi-squared test for trend was used.

Maps were produced using QGIS v3.49 (https:// www.ggis.org) using public domain shapefiles from the UK Ordnance Survey OpenData project.

#### Ethical Approval

THIN previously received approval for research using its database from the NHS South-East Multi-Centre Q19 Research Ethics Committee in 2003. This study received approval from the THIN Scientific Review Committee (reference 16THIN055).

#### Results

Overall, a total of 8,590,421 pseudonymized patient records with a total of approximately 53.3 million years of follow-up evaluation from 694 practices were

# ARTICLE IN PRESS

#### Webb et al 4

349

397

400

#### Clinical Gastroenterology and Hepatology Vol. ■, No. ■

Q34

407

Table 1. Incidence per 100,000 per Year of PBC, PSC, and AIH for the Time Period January 1, 2002 to 2016-05-10

	Subcategory	PBC			PSC			AIH		
Category		n	Incidence	95% CI	n	Incidence	95% CI	n	Incidence	95% CI
Population	_	1314	2.47	2.33–2.60	396	0.74	0.67–0.82	1034	1.95	1.83-2.07
Latitude	50°-	111	1.96	1.57–2.34	42	0.76	0.52-1.00	103	1.80	1.44-2.17
	51°-	373	1.86	1.67–2.06	135	0.65	0.54–0.75	359	1.75	1.57–1.93
	52°-	135	1.75	1.45–2.05	68	0.84	0.64–1.05	142	1.76	1.46-2.05
	53°-	220	2.76	2.40–3.13	60	0.75	0.56–0.94	157	1.97	1.66–2.28
	54°-	161	4.35	3.66–5.05	29	0.80	0.50–1.10	79	2.18	1.68–2.67
	55°-	151	4.06	3.31–4.80	33	0.89	0.56–1.22	88	2.35	1.77-2.92
	56°-	70	4.19	3.13–5.25	9	0.52	0.18–0.86	45	2.45	1.69–3.22
	57°-	86	4.55	3.52-5.58	18	0.98	0.50–1.46	58	3.06	2.18-3.93
	Missing	7	2.36	0.57–4.15	2	0.56	0.00–1.33	3	0.73	0.00-1.57
Sex	Male	173	0.66	0.56-0.76	230	0.91	0.79–1.03	241	0.94	0.82-1.06
	Female	1141	4.24	3.99-4.49	166	0.59	0.50-0.68	793	2.92	2.72-3.13
Age, <i>y</i>	0–9.9	0	0.00	0.00-0.00	2	0.00	0.00-0.00	7	0.12	0.00-0.26
	10–19.9	1	0.01	0.00-0.02	21	0.03	0.01-0.04	55	0.93	0.54–1.32
	20–29.9	5	0.07	0.01–0.13	34	0.05	0.03-0.07	48	0.62	0.44–0.8
	30–39.9	59	0.71	0.52–0.90	28	0.03	0.02–0.05	87	1.10	0.87–1.34
	40–49.9	181	1.94	1.65–2.23	68	0.08	0.06–0.10	132	1.45	1.20–1.70
	50–59.9	318	4.10	3.52-4.68	61	0.08	0.06–0.10	221	2.70	2.34-3.07
	60–69.9	353	5.08	4.53–5.63	87	0.14	0.10-0.17	239	3.68	3.13–4.23
	70–79.9	277	6.22	5.20-7.25	65	0.15	0.10–0.19	181	3.72	3.15-4.29
	80–89.9	111	4.28	3.20–5.36	28	0.09	0.05–0.13	61	2.34	1.67–3.00
	≥90	9	1.21	0.38–2.05	2	0.02	0.00–0.05	3	0.71	0.00–1.65
Deprivation	1 (least)	268	2.21	1.91–2.51	99	0.67	0.53–0.81	242	1.85	1.59–2.11
	2	287	2.43	2.14–2.72	88	0.74	0.58–0.91	225	1.90	1.65–2.16
	3	282	2.60	2.29–2.91	87	0.81	0.64–0.98	219	2.02	1.75–2.29
	4	244	2.62	2.28–2.96	69	0.80	0.61–1.00	175	1.95	1.65–2.25
	5 (most)	187	2.82	2.35–3.28	39	0.73	0.46-0.99	141	2.25	1.82-2.67
	Missing	46	2.86	1.93–3.79	14	0.75	0.35–1.15	32	1.76	1.06–2.45
Smoking	Smoker	400	3.40	3.03–3.77	54	0.47	0.33–0.61	256	2.24	1.94–2.55
	Ex-smoker	308	2.93	2.58–3.27	69	0.61	0.45–0.77	185	1.98	1.54–2.42
	Never smoker	596	1.96	1.80–2.12	265	0.95	0.83–1.07	578	1.96	1.79–2.12
	Missing	10	0.87	0.17–1.57	8	0.26	0.00–0.56	15	0.30	0.00-0.64

NOTE. Figures are adjusted for latitude, sex, age, Townsend<sup>30</sup> deprivation quintile, and smoking status by direct standardization as appropriate. Figures are per Q35 100,000 population/y with 95% Cls. Deprivation refers to Townsend<sup>30</sup> deprivation quintiles. See also Supplementary Table 2. 398

AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis. 399

examined. The first entry to follow-up was January 1, 401 2002, and the last data collection point was 2016-05-10. 402 The median follow-up period was 5.2 years (interquartile 403 range [IQR], 1.9-10.2 y). A total of 1314 incident cases of 404 PBC, 396 incident cases of PSC, and 1034 incident cases 405 of AIH were identified. 406

#### Incidence and Prevalence

The summary details of incident cases are provided in 460 Supplementary Tables 1 and 2. When assessed by linear 461 regression, there was no significant change in the inci-462 dence of any of PBC, PSC, or AIH over the study period Q20 463 (Supplementary Table 4 and Supplementary Figure 1). Q21 464

457 458 459

455

456

## RTICLE IN PRES

5

523

571

572

573

574

575

576

577

#### 2021

465

513

514

515

516

Table 2. Prevalence of PBC, PSC, and AlH in 2015

Category	Subcategory	PBC			PSC			AIH		
		n	Incidence	95% CI	n	Incidence	95% CI	n	Incidence	95% CI
Population	_	1299	39.62	37.50-41.74	353	10.77	9.65–11.88	1116	34.04	32.06–36.02
Latitude	50°-	83	28.16	21.88–34.44	27	9.71	5.87–13.55	93	32.19	25.38–39.0
	51°-	381	30.59	27.50–33.69	141	10.61	8.84–12.38	382	29.78	26.76-32.7
	52°-	84	27.29	21.44–33.15	30	9.90	6.29–13.50	88	29.00	22.89–35.1
	53°-	161	42.01	35.51–48.51	34	8.55	5.64–11.45	143	37.20	31.04–43.3
	54°-	153	63.86	53.70–74.02	27	11.41	7.09–15.74	98	42.69	34.10–51.3
	55°-	195	49.79	42.02–57.56	40	10.46	7.01–13.91	148	40.47	33.02-47.9
	56°-	103	60.95	48.53–73.36	18	10.63	5.67–15.58	71	41.00	31.17–50.8
	57°-	129	61.08	50.11-72.05	34	16.70	10.77–22.63	88	39.11	30.44-47.7
	Missing	10	37.40	15.06–59.74	2	8.51	0.00–19.85	5	18.50	3.98–33.03
Sex	Male	143	8.82	7.37–10.28	205	13.25	11.43–15.07	283	17.93	15.83–20.0
	Female	1156	69.35	65.36–73.33	148	8.69	7.28–10.09	833	50.36	46.92–53.7
Age	0-9.9	0	0.00	0.00-0.00	1	0.06	0.00–0.18)	2	2.55	0.00–7.43
	10-19.9	0	0.00	0.00-0.00	11	3.64	1.40–5.89	28	9.02	4.34–13.68
	20-29.9	2	0.77	0.00–1.95	33	7.23	4.14–10.32	67	16.74	10.76–22.7
	30-39.9	31	5.88	3.78–7.98	42	8.30	5.72–10.88	82	23.58	14.76–32.4
	40-49.9	121	21.04	17.27–24.82	44	9.09	5.44–12.73	132	28.08	18.51–37.6
	50-59.9	260	52.81	41.85–63.77	67	12.34	9.36–15.32	201	35.66	30.68-40.6
	60-69.9	363	84.44	70.06–98.82	73	15.81	12.07–19.55	279	68.96	55.14-82.7
	70-79.9	344	100.97	89.93–112.02	54	19.14	12.56–25.72	221	66.06	56.93–75.2
	80-89.9	163	84.97	70.48–99.46	26	12.41	7.34–17.49	97	57.29	44.49–70.1
	90+	15	29.64	13.90–45.37	2	3.38	0.00–7.90	7	33.83	0.96-66.69
Deprivation	1 – least	269	38.15	32.99-43.30	13	9.84	6.14–13.53	233	31.40	26.79–36.0
	2	295	43.15	38.50-48.36	88	11.92	9.67–14.69	261	35.87	31.40-40.3
	3	268	39.24	34.82-44.24	83	12.14	9.79–15.05	247	36.30	31.77-40.8
	4	256	41.82	37.00-47.27	70	10.25	8.11–12.96	189	32.09	27.41-36.7
	5 – most	175	40.28	34.74–46.72	64	10.45	8.18–13.36	156	37.31	30.60-44.0
	Missing	36	28.32	20.43–39.27	35	8.06	5.78–11.22	30	27.27	16.52–38.0
Smoking	Smoker	347	48.60	43.04–4.15	41	5.27	3.54-7.00	273	40.01	34.37–45.6
	Ex-smoker	351	52.55	46.96–58.13	60	8.49	6.19–10.80	234	36.33	31.46–41.2
	Never smoker	596	31.43	28.89–33.97	247	14.13	12.34–15.93	595	32.73	29.91–35.5
	Missing	5	10.69	0.61–20.77	5	3.92	0.00-8.14	14	23.31	8.09–38.55

NOTE. Figures are adjusted for latitude, sex, age, Townsend<sup>30</sup> deprivation quintile, and smoking status by direct standardization as appropriate. Figures are per 100,000 population with 95% CIs. Deprivation refers to Townsend<sup>30</sup> deprivation quintiles. See also Supplementary Table 3.

AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.

In 2015, the last full year of the study, a total of 1299 517 prevalent cases of PBC, 353 cases of PSC, and 1116 cases 518 of AIH were identified. Details of disease prevalence are 519 520 <sup>Q22</sup> summarized in Table 2 and Supplementary Table 3. The prevalence of all 3 diseases increased over time 521 (Supplementary Figure 2). Of those prevalent cases of 522


PSC in 2015, 52% had a lifetime diagnosis of ulcerative colitis, and 15% a lifetime diagnosis of Crohn's disease.

#### Latitude

578 To confirm whether a previously reported correlation 579 of incidence with latitude could be shown using this data 580

FLA 5.6.0 DTD ■ YJCGH57705 proof ■ 18 February 2021 ■ 6:24 pm ■ ce DVC

6 Webb et al



#### Clinical Gastroenterology and Hepatology Vol. ■, No. ■

set, the incidence of MS was assessed. The overall crude incidence of MS was 8.98 (8.75–9.23) per 100,000/y.

When assessed by latitude band after adjustment for 641 sex, age, smoking status, and Townsend<sup>30</sup> quintile, there 642 was a higher incidence of MS in the in the 57° band at 643 13.67 (11.86–15.48) per 100,000/y than in the  $50^{\circ}$ 644 latitude band at 8.24 (7.40-9.07) per 100,000/y 645 (Supplementary Figure 3 and Supplementary Table 5). 646 There was an increase in MS incidence of 0.66 647 (0.25-1.07) per 100,000/y per degree in latitude in-648 crease ( $r^2 = 0.721$ ; P = .008). By contrast, for hyper-649 tension, a disease not reported to have an association 650 with latitude, overall incidence was 946.26 651 (943.58-948.94) per 100,000/y with no significant cor-652 relation with latitude at -5.02 (-30.27 to 20.23) per Q23 653 100,000/y per degree in latitude ( $r^2 = 0.038$ ; P = .644) 654 (Supplementary Figure 3 and Supplementary Table 5). 655

For AILDs, the crude incidence of PBC was markedly 656 greater at more northerly latitudes (Table 1, 657 Supplementary Table 2, Figure 1, Figure 2, and 658 Supplementary Figure 4). After adjustment for sex, age, 659 smoking status, and Townsend<sup>30</sup> deprivation quintile, 660 there remained a more than doubling in incidence from 661 the 1.96 (1.57–2.34) per 100,000/y in the  $50^{\circ}$  latitude 662 band to 4.55 (3.52–5.58) per 100,000/y in the 57° lati-663 tude band. When assessed by linear regression, 664 PBC incidence increased by 0.46 (0.27–0.66) per 665 100,000/y per degree in latitude ( $r^2 = 0.850$ ; P = .001). 666 Similarly, but less markedly, the incidence of AIH was 667 greater at more northerly latitudes at 0.19 (0.11-0.26) 668 per 100,000/y per degree ( $r^2 = 0.873$ ; P < .001). 669 PSC incidence showed no significant correlation 670 with latitude at 0.01 (-0.02 to 0.04) per 100,000/y Q24 671  $(r^2 = 0.055; P = .577).$ 672

In 2015, after adjustment for age, sex, smoking status, and Townsend<sup>30</sup> quintile, there was a significant increase in the prevalence of both PBC and AIH at more northerly latitudes; such a gradient was not apparent for PSC (Table 2, Supplementary Table 3, and Figure 3). The prevalence of PBC increased by 5.61 (2.61–8.62) per 100,000 per degree of latitude ( $r^2 = 0.777$ , P = .003). For PSC, the prevalence did not change significantly at 0.64 (-0.14 to 1.40) per 100,000 per degree of latitude ( $r^2 = 0.406$ , P = .090). For AIH, the prevalence increased by 1.72 (0.36–3.08) per 100,000 per degree of latitude ( $r^2 = 0.616$ , P = .021).

**Figure 2.** Maps of the United Kingdom showing the crude incidence of autoimmune liver diseases. Incidences are for the whole study period and shown as cases per 100,000/y. The density of shading corresponds to incidence as denoted in each panel: (*A*) primary biliary cholangitis (PBC), (*B*) primary sclerosing cholangitis (PSC), and (*C*) autoimmune hepatitis (AIH). The locations of major cities are shown for reference.

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

639

640




Figure 3. Prevalence of autoimmune liver disease by latitude. Top row: Plots denote crude prevalence at the end of 2015 of (A) primary biliary cholangitis (PBC), (B) primary sclerosing cholangitis (PSC), and (C) autoimmune hepatitis (AIH). (D-F) Bottom row: Plots denote adjusted incidence after adjustment for sex, age, smoking status, and Townsend<sup>30</sup> deprivation quintile. For PBC, 5.89 (2.51–9.27) per 100,000 per degree ( $r^2 = 0.752$ ; P = .005); PSC, 0.62 (-0.18 to 1.41) per 100,000 per degree ( $r^2 = 0.33$ ) 0.375; P = .107; and AIH, 1.92 (0.150–3.69) per 100,000 per degree (r<sup>2</sup> = 0.540; P = .038).

Given the apparent differences in incidence between latitude bands, patient sex and age at presentation were assessed by latitude band. There was a significant trend toward the younger incidence of AIH at more northerly latitudes (-0.87; -1.49 to -0.25) years per degree ( $r^2 =$ 0.663, P = .014), but no significant difference in age for incident PBC or PSC, and no significant difference in incident sex ratios in any disease (Supplementary Tables 6 and 7).

#### Sex and Age

Over the whole study period, 1141 (86.8%) incident 740 025 cases of PBC were female, with a female:male ratio of 6.6:1; for PSC, 230 (58.1%) were male, with a 1.4:1 male:female ratio; for AIH, 793 (76.6%) were female, with a female:male ratio of 3.3:1. There was no significant change in the sex ratio of incident cases over time for any of the conditions (Supplementary Table 8). The median age of incident PBC was 63 years (IQR, 53-72 y); for PSC the median age was 57 years (IQR, 43-69 y); and for AIH the median age was 58 years (IQR, 44-69 y). The age of incidence did not change for PBC and PSC over the study period, but for AIH the median age at incidence increased (Supplementary Table 9).

#### Smoking

After adjustment for sex, age, Townsend<sup>30</sup> deprivation quintile, and latitude, incident PBC was more frequent in smokers than those who had never smoked at 3.40 (3.03-3.77) per 100,000/y and 1.96 (1.80-2.12) cases per 100,000/y, respectively. After the same adjustments, there was a lower incidence of PSC in smokers 0.47 (0.33-0.61) per 100,000/y compared with those who had never smoked 0.95 (0.83-1.07) per 100,000/y. For AIH, there was no difference between current smokers and those who had never smoked.

#### Deprivation

PBC was associated significantly with deprivation. The incidence was 2.21 (1.91-2.51) per 100,000/y, and in the most deprived quintile the incidence was 2.82 (2.35–3.28) per 100,000/y after adjustment for age, sex, latitude, and smoking status. When assessed by linear regression, there was an increase in incidence of 0.14 (0.08-0.20) per 100,000/y per Townsend<sup>30</sup> quintile  $(r^2 = 0.946; P = .005)$ . The incidence of PSC and AIH did not vary significantly with deprivation; deprivation varied with latitude (Supplementary Table 10)

#### 8 Webb et al

Ethnicitv

Discussion

### 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827

In this study we used aggregate data from a nation-828 ally representative cross-section of primary care prac-829 tices to show markedly greater incidences of both PBC 830 <sup>Q26</sup> and AIH at more northerly latitudes. For PBC there was a 831 greater than doubling of incidence over 70 of latitude; for 832 AIH there was an increase of more than 50%. These 833 observations persisted after correction for sex, age, 834 deprivation, and smoking status. For PBC, the difference 835 was notable for being more marked than the fold change 836 in incidence for MS in either this study or in meta-ana-837 lvses.<sup>24,25</sup> This observation may help future in-838 Q27 vestigations of the etiopathogenesis in PBC and AIH and 839 may explain some missing disease risk and variation 840 between our study and other studies. 841

Data on ethnicity were missing for 5,008,804 (58.3%)

registrations and a similar proportion of those diagnosed

with AILD (Supplementary Tables 2 and 3). Among the

minority with a recorded ethnicity, the crude incidence

and prevalence of PBC among those of white ethnicity

was greater than in those of non-white ethnicities. For

PSC and AIH, there were no significant differences. At-

tempts to adjust for covariables were not made because

of the high frequency of missing data.

One potential explanation for a disease correlation with 842 latitude is varying sunlight (ultraviolet light) exposure and 843 its effects on vitamin D metabolism. Such a pathway has 844 been proposed in PBC previously.<sup>21,34</sup> However, if this were 845 a major etiologic factor, patients with more pigmented skin 846 might be expected to be at increased risk.<sup>35</sup> Perhaps dif-847 ferences in sunlight exposure modulate genetic risk. In 848 addition, it is unclear as to what stage in life any exposure 849 effect from differing latitudes may occur and it is plausible 850 that it is childhood exposure that is most important.<sup>26</sup> 851 Expanding this work to other geographic areas is neces-852 sary. Equally, looking for similar correlations in disease 853 incidence and latitude in other diseases associated with low 854 vitamin D status such as inflammatory bowel disease would 855 be valuable.<sup>36</sup> In addition, environmental factors other than 856 vitamin D may be important. Smoking correlates with both 857 PBC and AIH incidence and it may be that our study has 858 undercorrected for these. Other environmental toxins that 859 have been proposed include toxic waste, coal, and hair 860 dve.<sup>10,37,38</sup> It is unknown as to how these might correlate 861 862 <sup>Q28</sup> with latitude. It is equally possible that some previously unconsidered factor perhaps relating to geology, diet, local 863 flora, or air quality is responsible for these results. In 864 addition, the genetic make-up of the United Kingdom varies 865 significantly with geography and it may be that our results 866 reflect an unrecognized genetic tendency.<sup>39</sup> 867

Two other observations within our results warrant 868 discussion in the context of others' work. First, we have 869 shown no correlation between PSC and latitude, whereas 870

#### Clinical Gastroenterology and Hepatology Vol. ■, No. ■

a high prevalence of PSC has been reported in the Nordic 871 countries, which are at northern latitudes.<sup>40</sup> Some of this 872 risk, however, may be genetic.<sup>41</sup> In addition, the Nordic 873 countries have low rates of smoking and are prosperous. 874 Notably, studies from Canada, which is also at a relatively 875 876 northerly latitude, do not record disproportionately high rates of PSC.<sup>5</sup> Second, we recorded a lower median age at 877 presentation among patients with AIH at more northern 878 latitudes in our cohort. Although this may correlate with 879 exposure to an unknown environmental factor, it also 880 may relate to genetic predisposition in the context of 881 known marked geographic genetic variations in the 882 United Kingdom.<sup>39</sup> Variations in age of presentation in 883 relation to HLA-D haplotype are well recognized in AIH, 884 as are variations in age of presentation internationally.<sup>3</sup> 885 To consider both questions more fully, additional 886 studies with consistent approaches to diagnosis based 887 over large and varying geographic areas are required. 888

Our estimates for incidence are close to those reported 889 elsewhere: in a recent meta-analysis, the population inci-890 891 dence of PSC across a number of countries was estimated at 0 to 1.3 per 100,000/y, and at 0.33 to 5.8 per 100,000/y 892 for PBC.<sup>5</sup> By comparison, in this study the overall incidence 893 was calculated at 0.74 per 100 000/y and 2.47 per 894 100,000/y, respectively. For AIH, meta-analyses are lack-895 ing, but 2 recent studies from Europe reported incidences 896 of 1.1 per 100,000/y and 1.7 per 100,000/y; we report an 897 incidence of 1.94 per 100,000/y.<sup>6,7</sup> Our overall prevalence 898 estimates also are similar to those published elsewhere. 899

There are likely to be differences in this cohort compared 900 with others. We reported median ages for the diagnosis of 901 AILD that are higher than those reported elsewhere. For 902 903 example, the median age at diagnosis of PBC in our cohort was 63 years; in the UK-PBC national cohort the median age 904 was 55 years.<sup>42</sup> For PSC, our median age was 57 years, the 905 International PSC Study Group reported a mean age at 906 diagnosis of 39 years.<sup>43</sup> Such differences may reflect age-907 associated differences in referral patterns to, or retention of 908 follow-up evaluation in, secondary care; bias in entry into 909 registries; or differences in diagnostic classification between 910 911 primary and secondary care. Furthermore, our work only 912 examined adults, whereas the International PSC Study Group cohort, for example, contained 13% of individuals aged 913 younger than 20. Our work has shown an apparent nar-914 rowing in the female:male ratio of patients referred for 915 transplantation in PBC.<sup>4</sup> In this study, there was no change 916 over time in the sex ratio for any disease including PBC. This 917 may reflect the reported poorer outcome for men than 918 919 women diagnosed with PBC, an observation that in turn has been related to later diagnosis.42 920

In this study we confirm the previously identified 921 dichotomous effect of smoking on AILD risk by showing 922 an association with increased incidence of both PBC and 923 924 AIH, but with decreased PSC risk. Notably, these associations persisted after controlling for deprivation, which 925 may be associated with smoking behavior.<sup>44</sup> We note 926 negative national trends in smoking over our study 927 period, although this study was not powered to show 928

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

differences in the duration of exposure and time from
exposure that might be expected to affect future AILD
epidemiology as national smoking trends change.<sup>45</sup>

932 Ethnicity, with its potential associations with both 933 genetics and environment, remains an incompletely un-934 derstood component of AILD risk. Interpreting the role of 935 ethnicity and disease risk in this study was hampered by 936 a large proportion of individuals not having a recorded 937 ethnicity and there being relatively few patients of non-938 white ethnicities. However, we do describe an approxi-939 mately doubled incidence of PBC in those of white 940 ethnicity as compared with those of other ethnicities. 941 Such an association has been described elsewhere, but 942 this large cohort underlines such differences.<sup>46</sup> We are 943 unable to comment on differences in the likelihood of 944 investigation for PBC in these populations or on disease 945 trajectory or severity at diagnosis described by others.<sup>47</sup>

946 This study had several strengths: its 14-year time 947 frame, large cohort size, the presence of information about 948 co-factors, and its derivation from primary care records 949 rather than secondary care records avoided the inherent 950 risk of selection bias in the latter. Potential weaknesses of 951 this study include the possibility of inaccurate recording of 952 diagnoses. We note, however, work suggesting that at least 953 Q29 for AIH, primary care Read codes are broadly represen-954 tative of specialist diagnoses.<sup>31</sup> Furthermore, although we have corrected for a major measure of socioeconomic 955 grouping by using Townsend<sup>30</sup> quintiles, we may have not 956 957 corrected sufficiently and some of the gradient in inci-958 dence we are seeing may reflect factors associated with 959 this such as dietary habits, exposure to environmental 960 toxins, or access to health care. In addition, we may have 961 underestimated the incidence of these diseases because of 962 our exclusion of overlapping disease and incident disease 963 within 1 year of joining a general practice. We cannot 964 exclude the existence of an alternative confounding factor 965 in relation to genetics, the environment, or medical prac-966 tice that would explain the variations in PBC and AIH seen 967 at different latitudes. We note specifically the existence of a center with a particular focus on AILDs in Newcastle in the 968 969 54° latitude band. Our findings require confirmation in a 970 different geographic region. A high proportion of in-971 dividuals did not have ethnicity recorded, meaning that 972 this was excluded from analysis and ethnicity represents a 973 further potential confounder. Finally, we were unable to 974 account for previous places of residence for individuals 975 who had changed location over time.

976 Here, we show a striking correlation between 977 increased geographic latitude and disease risk for PBC; 978 the same phenomenon is present to a lesser extent for 979 AIH, but absent for PSC. We also present key de-980 mographic information with regards to sex, age, depri-981 vation, and smoking status derived from primary care 982 data. Our results support a new avenue of investigation 983 in AILD etiology, provide primary care-derived estimates 984 of AILD epidemiology, and confirm others' findings 985 regarding the environmental impact of smoking, depri-986 vation, and ethnicity on the AILDs.

#### **Supplementary Material**

Note: To access the supplementary material accompanying this article, visit the online version of *Clinical Gastroenterology and Hepatology* at www.cghjournal.org, and at https://doi.org/10.1016/j.cgh.2021.01.029.

#### References

- 1. Hirschfield GM, Karlsen TH, Lindor KD, et al. Primary sclerosing cholangitis. Lancet 2013;382:1587–1599.
- Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 2013; 8:303–330.
- Webb GJ, Hirschfield GM, Krawitt EL, et al. Cellular and molecular mechanisms of autoimmune hepatitis. Annu Rev Pathol 2018;13:247–292.
- Webb GJ, Rana A, Hodson J, et al. Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists. Clin Gastroenterol Hepatol 2018;16:278–287 e7.
- Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56:1181–1188.
- 6. van Gerven NMF, Verwer BJ, Witte BI, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 2014;49:1245–1254.
- Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014;60:612–617.
- Lamba M, Ngu JH, Stedman CAM. Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis. Clin Gastroenterol Hepatol 2020. Epub ahead of print.
- Webb GJ, Hirschfield GM. Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun 2016; 66:25–39.
- Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 2010;59:508–512.
- 11. Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005;42:1194–1202.
- Corpechot C, Chretien Y, Chazouilleres O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010;53:162–169.
- Howel D, Fischbacher CM, Bhopal RS, et al. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology 2000;31:1055–1060.
- McNally RJ, James PW, Ducker S, et al. No rise in incidence but geographical heterogeneity in the occurrence of primary biliary cirrhosis in North East England. Am J Epidemiol 2014;179:492–498.
- van Erpecum KJ, Smits SJ, van de Meeberg PC, et al. Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology 1996;110:1503–1506.
- Mitchell SA, Thyssen M, Orchard TR, et al. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 2002;51:567–573.
- Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Rep 2010; 1043 4:311. 1044

# **ARTICLE IN PRESS**

#### 10 Webb et al

#### Clinical Gastroenterology and Hepatology Vol. ■, No. ■

- 104518. Gough A, Chapman S, Wagstaff K, et al. Minocycline induced1046autoimmune hepatitis and systemic lupus erythematosus-like1047syndrome. BMJ 1996;312:169–172.
- 1048
  19. Dankers W, Colin EM, van Hamburg JP, et al. Vitamin D in autoimmunity: molecular mechanisms and therapeutic potential.
  1050
  Front Immunol 2016;7:697.
- Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80(Suppl):1678S–1688S.
- 1054
   21. Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis. Semin Liver Dis 2014;34:265–272.
- Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007;66:1137–1142.
- Lucas RM, Ponsonby AL, Dear K, et al. Vitamin D status: multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient. J Steroid Biochem Mol Biol 2013;136:300–308.
- 106524.Simpson S Jr, Blizzard L, Otahal P, et al. Latitude is significantly<br/>associated with the prevalence of multiple sclerosis: a meta-<br/>analysis. J Neurol Neurosurg Psychiatry 2011;82:1132–1141.
- 25. Simpson S Jr, Wang W, Otahal P, et al. Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis. J Neurol Neurosurg Psychiatry 2019;90:1193–1200.
- 107126. Hypponen E, Laara E, Reunanen A, et al. Intake of vitamin D and<br/>risk of type 1 diabetes: a birth-cohort study. Lancet 2001;<br/>358:1500–1503.
- 1074
  1075
  1075
  1076
  27. Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010; 34:J168–J177.
- 1077 28. Blak BT, Thompson M, Dattani H, et al. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251–255.
- 1081 29. The Health Improvement Network [updated 2020-11-29]. Avail-1082 032 able from: https://www.the-health-improvement-network.com.
- 1083 30. Townsend P. Deprivation. J Social Policy 1987;16:125–146.
- 108431.Varyani F, Card T, Kaye P, et al. The communication of a secondary1085care diagnosis of autoimmune hepatitis to primary care practitioners:1086a population-based study. BMC Health Serv Res 2013;13:161.
- 1087<br/>108832.Maguire A, Blak BT, Thompson M. The importance of defining<br/>periods of complete mortality reporting for research using<br/>automated data from primary care. Pharmacoepidemiol Drug<br/>Saf 2009;18:76–83.
- 1091
  1092
  1092
  1093
  1093
  1094
  33. Mamtani R, Haynes K, Finkelman BS, et al. Distinguishing incident and prevalent diabetes in an electronic medical records database. Pharmacoepidemiol Drug Saf 2014;23:111–118.
- 34. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002;35:126–131.
- 1097
  1098
  1098
  1099
  1099
  1100
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000
  1000</l
- 36. Del Pinto R, Pietropaoli D, Chandar AK, et al. Association between inflammatory bowel disease and vitamin D deficiency: a systematic review and meta-analysis. Inflamm Bowel Dis 2015; 21:2708–2717.
- 110537. Dyson JK, Blain A, Shirley MDF, et al. Geo-epidemiology and<br/>environmental co-variate mapping of primary biliary cholangitis<br/>and primary sclerosing cholangitis. JHEP Rep 2020;3:100202.

 Smyk D, Mytilinaiou MG, Rigopoulou EI, et al. PBC triggers in water reservoirs, coal mining areas and waste disposal sites: 1109 from Newcastle to New York. Dis Markers 2010;29:337–344. 1110
 Leslie S, Winney B, Hellenthal G, et al. The fine-scale genetic structure of the British population. Nature 2015;519:309–314. 1112

1113

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

1139

1140

1141

1142

1143

1144

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

1170

**24**1145

Q30

- structure of the British population. Nature 2015;519:309–314.
  40. Lindkvist B, Benito de Valle M, Gullberg B, et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010;52:571–577.
- 41. Bergquist A, Montgomery SM, Bahmanyar S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008;6:939–943.
- Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144:560–569 e7; quiz e13–e14.
- 43. Weismuller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017;152:1975–1984 e8.
- Marston L, Carpenter JR, Walters KR, et al. Smoker, ex-smoker or non-smoker? The validity of routinely recorded smoking status in UK primary care: a cross-sectional study. BMJ Open 2014;4:e004958.
- 45. Simpson CR, Hippisley-Cox J, Sheikh A. Trends in the epidemiology of smoking recorded in UK general practice. Br J Gen Pract 2010;60:e121–e127.
- 46. Smyk D, Cholongitas E, Kriese S, et al. Primary biliary cirrhosis: family stories. Autoimmune Dis 2011;2011:189585.
- Peters MG, Di Bisceglie AM, Kowdley KV, et al. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology 2007;46:769–775.

#### Reprint requests

Address requests for reprints to: Gwilym J. Webb, MD, Cambridge Liver Unit, Addenbrooke's Hospital, Cambridge, United Kingdom. e-mail: gwilym.webb@ addenbrookes.nhs.uk; fax: (xxx) xxx-xxxx.

#### Acknowledgments

Data may be made available for further analysis in consultation with The Health Improvement Network

#### **CRediT Authorship Contributions**

Gwilym James Webb (Conceptualization: Equal; Formal analysis: Equal; Funding acquisition: Equal; Methodology: Equal; Visualization: Equal; Writing – original draft: Lead; Writing – review & editing: Equal) Ronan P Ryan (Data curation: Equal; Methodology: Equal) Tom P Marshall (Supervision: Equal; Writing – review & editing: Equal) Gideon M Hirschfield (Conceptualization: Equal; Funding acquisition: Equal; Supervision: Equal; Writing – review & editing: Equal)		
Conflicts of interest The authors disclose no conflicts.	<b>Q</b> 6	
Funding	<b>Q</b> 7	

Supported by the UK Medical Research Council Clinical Research Fellowship (G.J.W.), the UK National Institute for Health Research Birmingham Biomedical Research Unit (G.M.H. and T.M.), and an educational grant from Intercept pharmaceuticals (G.J.W. and G.M.H.). Supported by the UK Medical Research Council-funded UK-PBC stratified medicine platform (www.uk-pbc.com), an EU Career Development Award, support as Chief Investigator for UK-PSC (www.uk-psc.com), and a National Institute for Health Research Translational Research Collaboration (G.M.H.). Also supported by the National Institute for Health Research Applied Research Collaboration West Midlands (T.M.).

This report presents independent research funded in part by the National Institute for Health Research. The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health Q10 Research, or the Department of Health and Social Care.